Targeted Therapy: Kinase Inhibitors, Monoclonal Antibodies, and Conjugates

From poisoning division to fixing a fault

Classical chemotherapy attacks division in general. Targeted therapy attacks the specific molecular fault that drives a particular cancer. The shift began once we learned that many tumors are addicted to a single overactive protein — often a kinase-linked receptor or its downstream signal. Block that one protein and the cancer's growth engine stalls, while normal cells that do not depend on it are largely spared. The promise is far better selectivity than a poison aimed at all dividing cells.

Small molecules vs antibodies: the -nib and -mab split

A tyrosine kinase inhibitor is a small molecule (its name usually ends in -nib). Kinases are switches that pass growth signals along by adding phosphate groups; a tyrosine kinase inhibitor slips into the kinase's pocket and jams the switch off. Because they are small and oral, they reach targets inside the cell — including intracellular signaling enzymes. Imatinib, which shuts off the abnormal kinase of chronic myeloid leukaemia, turned a once-fatal disease into a manageable one and became the emblem of this whole approach.

A monoclonal antibody is a large protein (its name usually ends in -mab), a form of biologic therapy. Antibodies are too big to cross the cell membrane, so they work on the outside: latching onto a surface receptor to block its signal, or flagging the cancer cell for the immune system to destroy. Trastuzumab binds the HER2 receptor over-expressed on certain breast cancers; rituximab tags a marker on B-cell lymphomas. Same goal, different real estate — inside the cell for -nib, on the surface for -mab.

Targeted therapy: where each kind acts

  outside cell  |   cell membrane   |  inside cell
  ------------- | ----------------- | -------------
  -mab antibody | surface receptor  |
  (large, IV)   |  -- blocked -->   |
                |    receptor       |
                |       |           |
                |       v           |
                |   signal relay -->  -nib inhibitor jams the
                |                     kinase switch (small, oral)

Rule of thumb:  -mab = outside / surface;  -nib = inside / kinase

Antibody-drug conjugates: a guided missile

What if you took the precision of an antibody and the killing power of a cytotoxic, and tied them together? That is an antibody-drug conjugate: a monoclonal antibody that homes in on a tumor surface marker, chemically linked to a potent cell poison. The antibody is the guidance system; the attached toxin is the warhead. The conjugate circulates harmlessly until the antibody docks on a cancer cell, the cell swallows it, and only then is the toxin released inside the target. This lets you use poisons far too dangerous to give on their own.